LIDOCAINE HYDROCHLO

Cardinal Health, Inc. (CAGE 00E55) has been awarded a delivery order under the Defense Logistics Agency’s IDIQ contract SPE2DX25D8022 for the supply of one pharmaceutical unit of lidocaine hydrochloride, identified by NSN 6505015865691 and NDC 00040-1409-01, at a unit price of $17.26, resulting in a total contract value of $17.26 for this specific order. The delivery is scheduled for July 20, 2026, with FOB destination terms requiring the contractor to bear all costs and risks until the item is delivered and accepted at the designated location: Naval Medical Readiness Logistics Command, Cheatham Annex, Williamsburg, Virginia. Inspection and acceptance are conducted by the government at the destination, and conformity to contract specifications is the sole criterion for acceptance. The contract is structured as a commercial item acquisition under FAR 52.212-4 and 52.212-5, incorporating standard commercial terms and conditions required to implement statutes and executive orders. Payment will be processed by Defense Finance and Accounting Service in Columbus, Ohio, using the accounting code 97X4930 5CBX 001 2620 S33189, with Fast Pay Net 15 terms applicable. The contractor is required to mark all packages with the identification numbers from Blocks 1 and 2 of the contract, using block text for clarity, though no specific MIL-STD for packaging, preservation, or barcoding is cited. The contract does not include socioeconomic set-asides, and Cardinal Health, Inc. is classified as other than a small business with no certifications for small disadvantaged, women-owned, 8(a), or HUBZone status. The award is part of a larger IDIQ contract with a ceiling of $20,000,000, though this order represents a single, non-recurring line item with zero tolerance for quantity variance. Electronic invoicing via EDI is required, and duplicate shipments are prohibited. The contracting officer is Lorinda Ferraiolo, with administrative support provided by Michelle Pampel and Catherine Gilbert, and the government representative overseeing acceptance is Lisa Quinn. No option periods, modification numbers, or special clauses relating to security, personnel, or conflicts of interest are present,